Aurora González‐Fierro

Author

Also Known As

A González-Fierro, A. Gonzalez-Fierro, A. González-Fierro, AURORA GONZALEZ-FIERRO, Aurora Gonzalez-Fierro, Aurora Gonzalez‑Fierro, Aurora González-Fierro, Aurora González‐Fierro

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Instituto Nacional de Cancerología Universidad Nacional Autónoma de México Universidad de Cuautitlán Izcalli

About

Aurora González‐Fierro is an author at Instituto Nacional de Cancerología specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	579
2	Public Health	1	1	18
3	Biomolecular Engineering	1	1	62
4	Cell Biology	1	1	62
5	Obstetrics	1	1	131

Aurora González‐Fierro

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Annals of Oncology Chemotherapy ResistanceMedicinePharmacologyMagnesium ValproatePharmacotherapy	2007	249
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro, PLoS ONE	2006	144
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines Alma Chávez‐Blanco, Carlos Pérez‐Plasencia, Enrique Pérez‐Cárdenas, Cancer Cell International	2006	142
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results Jaime Coronel, Lucely Cetina, Irlanda Pacheco, Medical Oncology Advanced Cervical CancerCervical CancerMedicinePharmacologyClinical Trials	2010	131
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Alma Chávez‐Blanco, Blanca Segura-Pacheco, Enrique Pérez‐Cárdenas, Molecular Cancer	2005	127
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Myrna Candelaria, Aquileo Herrera, Juan Labardini, Annals of Hematology Hematological MalignancyEpigenetic TreatmentHematologyPharmacologyMagnesium Valproate	2010	72
HER2 expression in cervical cancer as a potential therapeutic target Alma Chávez‐Blanco, Víctor M. Pérez-Sánchez, Aurora González‐Fierro, BMC Cancer	2004	65
Ivermectin as an inhibitor of cancer stem‑like cells Guadalupe Domínguez-Gómez, Alma Chávez‐Blanco, José L. Medina‐Franco, Molecular Medicine Reports Ivermectin TreatmentIvermectin ExposureBreast Cancer CellMedicineStem Cell Toxicology	2017	62
Circulating nucleosomes and response to chemotherapy: An <i>in vitro</i>, <i>in vivo</i> and clinical study on cervical cancer patients Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, Homero Treviño‐Cuevas, International Journal of Cancer	2003	61
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells Myrna Candelaria, Erick de la Cruz‐Hernandez, Lucía Taja‐Chayeb, PLoS ONE	2012	51

Page 1